GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
GO:004580710 | Oral cavity | OSCC | positive regulation of endocytosis | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:00725838 | Oral cavity | OSCC | clathrin-dependent endocytosis | 30/7305 | 47/18723 | 4.96e-04 | 2.92e-03 | 30 |
GO:004825910 | Oral cavity | OSCC | regulation of receptor-mediated endocytosis | 58/7305 | 110/18723 | 2.37e-03 | 1.05e-02 | 58 |
GO:003010023 | Oral cavity | EOLP | regulation of endocytosis | 51/2218 | 211/18723 | 4.24e-07 | 1.19e-05 | 51 |
GO:007258321 | Oral cavity | EOLP | clathrin-dependent endocytosis | 19/2218 | 47/18723 | 6.00e-07 | 1.56e-05 | 19 |
GO:000689825 | Oral cavity | EOLP | receptor-mediated endocytosis | 55/2218 | 244/18723 | 1.64e-06 | 3.82e-05 | 55 |
GO:004580724 | Oral cavity | EOLP | positive regulation of endocytosis | 27/2218 | 100/18723 | 2.69e-05 | 3.94e-04 | 27 |
GO:004825915 | Oral cavity | EOLP | regulation of receptor-mediated endocytosis | 28/2218 | 110/18723 | 6.12e-05 | 7.68e-04 | 28 |
GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
GO:00482689 | Oral cavity | EOLP | clathrin coat assembly | 8/2218 | 18/18723 | 5.58e-04 | 4.74e-03 | 8 |
GO:00482609 | Oral cavity | EOLP | positive regulation of receptor-mediated endocytosis | 14/2218 | 52/18723 | 2.31e-03 | 1.42e-02 | 14 |
GO:003010031 | Oral cavity | NEOLP | regulation of endocytosis | 47/2005 | 211/18723 | 7.96e-07 | 2.20e-05 | 47 |
GO:000689831 | Oral cavity | NEOLP | receptor-mediated endocytosis | 51/2005 | 244/18723 | 2.08e-06 | 4.87e-05 | 51 |
GO:004580731 | Oral cavity | NEOLP | positive regulation of endocytosis | 27/2005 | 100/18723 | 4.19e-06 | 9.05e-05 | 27 |
GO:004826813 | Oral cavity | NEOLP | clathrin coat assembly | 9/2005 | 18/18723 | 3.59e-05 | 5.21e-04 | 9 |
GO:007258331 | Oral cavity | NEOLP | clathrin-dependent endocytosis | 15/2005 | 47/18723 | 7.12e-05 | 9.27e-04 | 15 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SGIP1 | SNV | Missense_Mutation | | c.2416G>C | p.Val806Leu | p.V806L | Q9BQI5 | protein_coding | tolerated(0.05) | benign(0.345) | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
SGIP1 | SNV | Missense_Mutation | rs369259312 | c.1241N>T | p.Pro414Leu | p.P414L | Q9BQI5 | protein_coding | tolerated(0.3) | benign(0.193) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
SGIP1 | SNV | Missense_Mutation | | c.2425N>T | p.Gly809Trp | p.G809W | Q9BQI5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SGIP1 | SNV | Missense_Mutation | novel | c.2423C>A | p.Ala808Glu | p.A808E | Q9BQI5 | protein_coding | deleterious(0.02) | benign(0.087) | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SGIP1 | SNV | Missense_Mutation | rs556202457 | c.475N>T | p.Arg159Cys | p.R159C | Q9BQI5 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SGIP1 | SNV | Missense_Mutation | novel | c.247N>A | p.Glu83Lys | p.E83K | Q9BQI5 | protein_coding | deleterious(0.01) | benign(0.173) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
SGIP1 | SNV | Missense_Mutation | | c.2269N>A | p.Pro757Thr | p.P757T | Q9BQI5 | protein_coding | tolerated(0.23) | benign(0.127) | TCGA-E2-A155-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SGIP1 | SNV | Missense_Mutation | | c.2283N>T | p.Gln761His | p.Q761H | Q9BQI5 | protein_coding | tolerated(0.17) | benign(0.115) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SGIP1 | SNV | Missense_Mutation | novel | c.1483N>A | p.Pro495Thr | p.P495T | Q9BQI5 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SGIP1 | SNV | Missense_Mutation | | c.574G>A | p.Asp192Asn | p.D192N | Q9BQI5 | protein_coding | tolerated(0.34) | benign(0.086) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |